Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2023 | Platelet aggregation inhibitor glenzocimab as an add-on therapy to thrombolysis

James Grotta, MD, Memorial Hermann-Texas Medical Center, Houston, TX introduces glenzocimab, a platelet GPVI receptor antagonist with the unique ability to block platelet adhesion without increasing bleeding risk. Early investigations and the ongoing ACTISAVE trial (NCT05070260) shed light on its potential to reduce bleeding after ischemic stroke, particularly in severe cases. Glenzocimab is also thought to have anti-inflammatory effects, reducing damage upon reperfusion, and ultimately leading to reduced bleeding. The Phase II randomized, double blind, placebo controlled ACTISAVE trial is underway in both Europe and the US. It aims to evaluate glenzocimab’s capacity to amplify the effects of thrombolysis with or without thrombectomy following an ischemic stroke. Preliminary blinded safety data from the first 100 participants, presented at the World Stroke Congress 2023, already reveal a low bleeding rate in relatively severe strokes. We await the full results of this trial, expected in mid-2024, to understand glenzocimab’s impact on stroke outcomes. This interview took place at the World Stroke Congress (WSC) 2023 in Toronto, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


James Grotta reports the following disclosures: I am on the scientific advisory board for Acticor, and am U.S. Principle Investigator for the ACTISAVE study. Acticor manufactures Glenzocimab. I am a consultant for Frazer Ltd, a company that manufactures Mobile Stroke Units.